Rapamune Off-Label Promotion – Multi-State Settlement
Pfizer agreed to pay $35 million to 41 states and the District of Columbia to resolve allegations that Wyeth Pharmaceuticals (acquired by Pfizer in 2009) promoted off-label uses for its Rapamune kidney transplant drug. Wyeth allegedly engaged in off-label marketing, promoting the drug for uses that were not approved by the Food and Drug Administration. Wyeth also allegedly violated state consumer protection laws by misrepresenting Rapamune’s uses and benefits through an orchestrated campaign of promotional talks by Wyeth-retained doctors, misleading presentations of data, and company-funded studies at hospitals and transplant centers designed to encourage off-label uses of Rapamune. In July 2013, Wyeth paid $490.9 million and pleaded guilty in a legal matter involving similar allegations. (see Pfizer, Inc. instance, “Sandler et al. v. Wyeth Pharmaceuticals”).
- Misconduct Type
- Enforcement Agency
- Contracting Party
- Court Type
- Date of Settlement Announcement